OPEN ACCESS Freely available online

Journal of Bone Research

Short Communication

Emerging Biomarkers for Early Diagnosis of Bone-Related Disorders

Ritu Saxorna*

Department of Osteology, university of delhi, New Delhi, India.

ABOVE THE STUDY

Bone-related disorders, including osteoporosis, osteoarthritis, and metabolic bone diseases, are often diagnosed at advanced stages when structural damage has already occurred. Early detection remains a significant clinical challenge, as conventional diagnostic tools such as Bone Mineral Density (BMD) measurements and radiographic imaging lack sensitivity for identifying subtle, early changes in bone metabolism. In recent years, the identification of novel biomarkers has emerged as a promising strategy for improving early diagnosis, risk stratification, and therapeutic monitoring in bone diseases.

Biomarkers of bone turnover are broadly categorized into markers of bone formation and bone resorption. Traditional formation markers include osteocalcin and Bone-Specific Alkaline Phosphatase (BSAP), while resorption markers include C-terminal telopeptide of type I collagen (CTX) and N-terminal Telopeptide (NTX). Although these markers provide valuable insights into bone remodeling dynamics, their variability and limited specificity restrict their utility in early diagnosis [1]. This has driven the search for more sensitive and specific biomarkers that reflect underlying molecular and cellular processes.

One of the most promising areas of biomarker research involves microRNAs (miRNAs), small non-coding RNAs that regulate gene expression post-transcriptionally. Circulating miRNAs are stable in body fluids and have been shown to correlate with bone metabolism and disease states. Specific miRNAs, such as miR-21, miR-29, and miR-133, have been associated with osteoblast and osteoclast activity, making them potential candidates for early detection of osteoporosis and other bone disorders [2]. Their ability to reflect real-time changes in cellular function positions them as highly informative biomarkers.

Another emerging class of biomarkers includes proteins involved in signaling pathways critical for bone homeostasis. Sclerostin, a glycoprotein produced by osteocytes, acts as an inhibitor of the Wnt/β-catenin pathway and has been linked to reduced bone formation. Elevated serum sclerostin levels have been observed in aging populations and individuals with osteoporosis, suggesting its potential as an early indicator of impaired bone formation [3]. Similarly, dickkopf-1 (DKK1), another Wnt pathway inhibitor, has been implicated in bone loss and may serve as a complementary biomarker [4].

Advances in proteomics and metabolomics have further expanded the landscape of potential biomarkers. Proteomic analyses have identified novel proteins associated with bone matrix turnover, inflammation, and mineralization. Metabolomic profiling, on the other hand, has revealed alterations in metabolic pathways related to amino acids, lipids, and energy metabolism in individuals with bone disorders [5]. These high-throughput approaches enable the identification of biomarker panels that may provide greater diagnostic accuracy than single markers.

Inflammatory markers are also gaining attention in the context of bone health. Chronic low-grade inflammation is a known contributor to bone loss, particularly in aging and autoimmune conditions. Cytokines such as Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α) have been associated with increased osteoclast activity and reduced bone formation. Elevated levels of these cytokines may serve as early indicators of bone remodeling imbalance [6].

Circulating extracellular vesicles, including exosomes, represent another promising source of biomarkers. These vesicles carry proteins, lipids, and nucleic acids reflective of their cells of origin. Exosomal miRNAs and proteins have been shown to influence bone remodeling and may provide insights into early pathological changes [7]. Their stability and accessibility in body fluids make them attractive candidates for non-invasive diagnostics.

Despite these advances, several challenges must be addressed before these biomarkers can be widely implemented in clinical practice. Standardization of sample collection, processing, and analysis is essential to ensure reproducibility and comparability across studies. Additionally, the influence of factors such as age, sex, diet, and comorbidities on biomarker levels must be carefully considered [8]. Large-scale, longitudinal studies are needed to validate the clinical utility of these biomarkers and establish reference ranges.

Integration of biomarker data with advanced imaging techniques and clinical parameters may further enhance diagnostic accuracy.

Correspondence to: Ritu Saxena. Department of Osteology, university of delhi, New Delhi, India. E-mail: ritu.saxorna@tmc.gov.in

Received: 24-Feb-2025, Manuscript No. BMRJ-25- 41373; **Editor assigned:** 26-Feb-2025, PreQC No. BMRJ-25-41373 (PQ); **Reviewed:** 12-Mar-2025, QC No. BMRJ-25-41373; **Revised:** 19-Mar-2025, Manuscript No. BMRJ-25-41373 (R); **Published:** 26-Mar-2025. DOI: 10.35841/2572-4916.25.13.330.

Citation: Saxorna R (2025). Emerging Biomarkers for Early Diagnosis of Bone-Related Disorders. J Bone Res. 13:330.

Copyright: © 2025 Saxorna R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Machine learning and artificial intelligence approaches are being explored to analyze complex datasets and identify patterns predictive of early bone disease [9]. Such integrative strategies hold promise for personalized medicine, enabling tailored interventions based on individual risk profiles.

In conclusion, emerging biomarkers offer significant potential for the early diagnosis of bone-related disorders. From miRNAs and signaling proteins to metabolomic and exosomal markers, these novel indicators provide deeper insights into the molecular mechanisms underlying bone health and disease. While challenges remain, continued research and technological advancements are likely to pave the way for their integration into routine clinical practice, ultimately improving patient outcomes through earlier detection and intervention [10].

REFERENCES

1. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis international. 2011;22:391-420.
2. Weilner S, Skalicky S, Salzer B, Keider V, Wagner M, Hildner F, et al. Differentially circulating miRNAs after recent osteoporotic fractures can influence osteogenic differentiation. Bone. 2015;79:43-51.
3. Riddle RC. Endocrine functions of sclerostin. Current opinion in endocrine and metabolic research. 2023;28:100433.
4. Baron R, Kneissel M. Wnt signaling in bone homeostasis and disease. Nat Med. 2013;19:179–192.
5. Lau KT, Krishnamoorthy S, Sing CW, Cheung CL. Metabolomics of osteoporosis in humans: a systematic review. Current Osteoporosis Reports. 2023;21:278-88.
6. Schett G. Effects of inflammatory and anti-inflammatory cytokines on the bone. Eur J Clin Invest. 2011;41:1361–1366.
7. Li Q, Huang QP, Wang YL, Huang QS. Extracellular vesicle-mediated bone metabolism in the bone microenvironment. Journal of Bone and Mineral Metabolism. 2018;36:1-1.
8. Eastell R, Pigott T, Gossiel F, Naylor KE, Walsh JS, Peel NF, et al. Diagnosis of endocrine disease: bone turnover markers: are they clinically useful?. European journal of endocrinology. 2018;178:R19-31.
9. D'Angelo T, Caudo D, Blandino A, Albrecht MH, Vogl TJ, Gruenewald LD, et al. Artificial intelligence, machine learning and deep learning in musculoskeletal imaging: current applications. Journal of Clinical Ultrasound. 2022;50:1414-31.
10. Garnero P. The utility of biomarkers in osteoporosis management. Molecular diagnosis & therapy. 2017;21:401-18.